Papatheodoridis, G. V. Et Al. 2016. Hepatocellular carcinoma HCC is the only factor affect ing the excellent survival of Caucasian chronic hepatitis B CHB patients with or without cirrhosis under long term entecavir ETV or tenofovir TDF therapy. American Association of Study of Liver disease (AASLD) 2016 .

Papatheodoridis, G. V., Dalekos, G. N., YURTAYDIN, S. C., van Bömmel, F., Buti, M., Sypsa, V., ... Goulis, J.(2016). Hepatocellular carcinoma HCC is the only factor affect ing the excellent survival of Caucasian chronic hepatitis B CHB patients with or without cirrhosis under long term entecavir ETV or tenofovir TDF therapy . American Association of Study of Liver disease (AASLD) 2016

Papatheodoridis, ONUR Et Al. "Hepatocellular carcinoma HCC is the only factor affect ing the excellent survival of Caucasian chronic hepatitis B CHB patients with or without cirrhosis under long term entecavir ETV or tenofovir TDF therapy," American Association of Study of Liver disease (AASLD) 2016, 2016

Papatheodoridis, ONUR Et Al. "Hepatocellular carcinoma HCC is the only factor affect ing the excellent survival of Caucasian chronic hepatitis B CHB patients with or without cirrhosis under long term entecavir ETV or tenofovir TDF therapy." American Association of Study of Liver disease (AASLD) 2016 , 2016

Papatheodoridis, G. V. Et Al. (2016) . "Hepatocellular carcinoma HCC is the only factor affect ing the excellent survival of Caucasian chronic hepatitis B CHB patients with or without cirrhosis under long term entecavir ETV or tenofovir TDF therapy." American Association of Study of Liver disease (AASLD) 2016 .

@conferencepaper{conferencepaper, author={ONUR KESKİN Et Al. }, title={Hepatocellular carcinoma HCC is the only factor affect ing the excellent survival of Caucasian chronic hepatitis B CHB patients with or without cirrhosis under long term entecavir ETV or tenofovir TDF therapy}, congress name={American Association of Study of Liver disease (AASLD) 2016}, city={}, country={}, year={2016}}